Fang Shi

Fang Shi

Auto-generated profile, based on publicly available information

Fang Shi

Laboratory of Neuroscience, The first Affiliated Hospital of Guilin Medical University, Guilin, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2026 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
MMMuyan Ma
Muyan Ma
FSFang Shi
Fang Shi
JZJY ZHU
JY ZHU
Alzheimer’s disease (AD) represents a major neurodegenerative threat, with elevated Interleukin-6 (IL-6) levels increasingly recognized as a key player in its pathology. However, the mechanistic links between IL-6 signaling and AD progression remain largely elusive. To address this gap, we employed an integrated approach combining bioinformatics, molecular biology, and preclinical models to dissect IL-6’s multifaceted role in AD pathogenesis. Protein-protein interaction (PPI) network analysis identified IL-6 and its receptor (IL-6R) as key hub genes. Experimental validation in SHSY5Y-APP cellular AD models confirmed significant upregulation of IL-6, IL-6R, and soluble IL-6R(sIL-6R) compared to control groups, validating our bioinformatics predictions. Moreover, our results reveal a striking dichotomy in IL-6 signaling: classical signaling activation promotes Aβ production, while trans-signaling exerts inhibitory effects. This trans-signaling mechanism mediates the upregulation of ADAM17 expression through JAK/STAT3 pathway activation. Notably, treatment with TAPI-1, a specific ADAM17 inhibitor, abolished both the ADAM17 upregulation and the associated Aβ reduction, confirming the pathway’s specificity. In vivo studies in APP/PS1 transgenic mice further demonstrated that trans-signaling activation not only restored spatial memory deficits but also attenuated hippocampal Aβ deposition. Collectively, this work indicates a novel positive feedback loop between IL-6 trans-signaling and ADAM17 that suppresses Aβ accumulation in AD pathology. These results highlight the therapeutic potential of targeting IL-6 trans-signaling pathways to mitigate pathological Aβ accumulation.